To confirm the safety of the Gastrointestinal hormone Ghrelin against chronic kidney disease patients
- Conditions
- Chronic Kidney Disease
- Registration Number
- JPRN-jRCTs031180354
- Lead Sponsor
- Itoh Hiroshi
- Brief Summary
We focused on a peptide hormone ghrelin. Due to the antioxidative effect of ghrelin, we thought that it might be effective against chronic kidney disease patients by improving the protein energy waisting syndrome and slowing down the progression of kidney dysfunction. There were many candidates but we could not make an agreement to participate in this study. We terminated this study because of the difficulty in obtaining ghrelin from the company.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 0
Age 20 and up
Stage G4 and G5 Chronic Kidney Disease Patient of Keio University Hospital outpatient clinic who have not underwent dialysis
BMI lower than 25
Who have agreed to cooperate with this clinical study with an excellent understanding
Who have severe liver dysfunction
Who have cancer
Who have severe infectious disease
Who have mental disorders
Who have allergy against wheat, eggs and milk
Women with a possibility of pregnancy
Who have been decided to be excluded by the primary doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time course of the blood concentration of Ghrelin
- Secondary Outcome Measures
Name Time Method Percentage of the appearance of the side effects of Ghrelin